UNITED THERAPEUTICS CORPORATION
About UNITED THERAPEUTICS CORPORATION
United Therapeutics Corporation is an American biotechnology company that develops pharmaceuticals and technologies related to organ transplantation, including xenotransplantation. Many of the company's products are focused towards lung diseases. It was founded in 1996 by Martine Rothblatt. The company has six FDA-approved therapies that treat PAH, pulmonary hypertension associated with interstitial lung disease (PH-ILD), and neuroblastoma.
- 🔗 United Therapeutics Corporation - 2026 Company Profile & Competitors - Tracxn
- 🔗 United Therapeutics - Wikipedia
- 🔗 United Therapeutics Investor Relations
- 🔗 United Therapeutics Converts to a Public Benefit Corporation Following Shareholder Approval
- 🔗 United Therapeutics Corporation Common Stock (UTHR) Stock Price, Quote, News & History | Nasdaq
Investors
Not disclosed in the source filing. Form D filings do not list investors — StreetZero surfaces them from news where available.
Key highlights
- Converted to public benefit corporation in 2021 as first public biotech to do so.
- Founded in 1996 by Martine Rothblatt to address daughter's pulmonary arterial hypertension.
- Six FDA-approved therapies for PAH, PH-ILD, and neuroblastoma.
- Announced accelerated share repurchase under $2.0B authorization.
- Reported 2025 revenue of $3.18 billion.
Ask StreetZero about UNITED THERAPEUTICS CORPORATION
Put our AI to work on this deal.
Similar companies
Other Public Equity (NASDAQ) deals, ranked by Signal.
Source document & SEC filing
The source SEC filing and the cached document are available to members only. Sign in to view and download them.
Sign in to view the filing Create free account